Testing three CDK4/6 pills to change the immune response
Treatments studied
Part of Cancer, Skin clinical trials.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 20 or older
- Your breast cancer is estrogen-receptor positive (ER) and HER2 negative based on tissue or cell tests
- You have early breast cancer stage II to III
- Your body is functioning well enough for the study treatment (organ function is adequate)
- Your daily functioning is good (ECOG 0–1)
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer targeted therapy (dalpiciclib) causes fewer side effects than two similar drugs (abemaciclib and ribociclib) in people with early-stage, hormone receptor-positive, HER2-negative breast cancer after surgery. The goal is to find a better-tolerated treatment to reduce the risk of cancer returning.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.